• SPX
  • $5,992.19
  • 0.32 %
  • $19.09
  • DJI
  • $43,990.04
  • 0.6 %
  • $260.69
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,070.33
  • -0.86 %
  • -$70.41
  • IXIC
  • $19,244.42
  • -0.13 %
  • -$25.04
Bionano Genomics, Inc. (BNGO) Stock Price, News & Analysis

Bionano Genomics, Inc. (BNGO) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.28

-$0.02

(-5.8%)

Day's range
$0.27
Day's range
$0.3
50-day range
$0.2626
Day's range
$0.5086
  • Country: US
  • ISIN: US09075F3055
52 wk range
$0.26
Day's range
$2.27
  • CEO: Dr. Robert Erik Holmlin M.B.A., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -8.58
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (BNGO)
  • Company Bionano Genomics, Inc.
  • Price $0.28
  • Changes Percentage (-5.8%)
  • Change -$0.02
  • Day Low $0.27
  • Day High $0.30
  • Year High $2.27

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/08/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $2.00
  • High Stock Price Target $175.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$6.18
  • Trailing P/E Ratio -0.14
  • Forward P/E Ratio -0.14
  • P/E Growth -0.14
  • Net Income $-232,493,000

Income Statement

Quarterly

Annual

Latest News of BNGO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Bionano Genomics (BNGO) Q2 2024 Earnings Call Transcript

    Welcome to Bionano's Q2 financial results call. CEO Erik Holmlin and CFO Gulsen Kama lead the discussion. Revenue is $7.8 million, impacted by discontinued clinical services. The focus is on cost savi...

    By Yahoo! Finance | 3 months ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.